8-K: Zenas BioPharma Expands Pipeline, Secures $120M in Financing

Zenas BioPharma announced a transformative license agreement with InnoCare Pharma for three autoimmune product candidates, including a Phase 3 BTK inhibitor for MS, and a $120 million private placement financing.

Summary

• Zenas BioPharma entered a license agreement with InnoCare Pharma for global development and commercialization rights to three autoimmune product candidates.
• The lead candidate, orelabrutinib, a highly selective CNS-penetrant BTK inhibitor, is now in Phase 3 development for progressive forms of Multiple Sclerosis (MS).
• Zenas secured global rights for orelabrutinib in MS and all non-oncology indications outside Greater China and Southeast Asia.
• The agreement also includes exclusive rights to ZB021 (oral IL-17AA/AF inhibitor) and ZB022 (oral, brain-penetrant TYK2 inhibitor) in specified territories.
• Zenas will pay InnoCare an upfront cash payment of $35 million and issued 5,000,000 shares of its common stock.
• Additional payments to InnoCare include a $25 million cash payment and 2,000,000 shares upon an orelabrutinib near-term milestone (earlier of Phase 3 initiation for non-PPMS or March 31, 2026).
• Potential milestone payments to InnoCare could reach up to $723 million for orelabrutinib and $656 million each for ZB021 and ZB022, plus tiered royalties.
• Zenas also announced a private placement financing expected to raise approximately $120.0 million in gross proceeds.
• This financing involves issuing approximately 6.3 million shares of common stock to institutional and accredited investors at $19.00 per share, and to certain directors and officers at $20.85 per share.
• The PIPE closing is anticipated on or about October 9, 2025.
• As of September 30, 2025, Zenas had approximately $302 million in existing cash, cash equivalents, and investments.
• The company expects its cash runway to extend into Q4 2026, and into Q1 2027 assuming a $75 million milestone from Royalty Pharma for the INDIGO trial.

Sentiment

Score: 8

Explanation: The company has significantly expanded its pipeline with promising late-stage and early-stage assets, particularly in the high-value MS market, and secured substantial financing to extend its operational runway. While there are risks, including a partial clinical hold for one indication of orelabrutinib, the overall strategic moves and clinical progress are highly positive.

Positives

• Significant expansion of the pipeline with three new autoimmune product candidates, including a late-stage BTK inhibitor for MS.
• Orelabrutinib, a potentially best-in-class CNS-penetrant BTK inhibitor, has initiated a Phase 3 trial for Primary Progressive MS (PPMS) and plans to initiate a Phase 3 trial for Secondary Progressive MS (SPMS) in Q1 2026.
• Positive Phase 2 data for orelabrutinib in Relapsing-Remitting MS (RRMS) showed rapid and deep reduction in new Gd+ T1 lesions (up to 90.4% reduction at Week 12 for 80mg QD).
• The $120 million private placement financing strengthens the company's financial position and extends its cash runway.
• The license agreement with InnoCare Pharma, a globally recognized company, validates the potential of the acquired assets.
• ZB021 (oral IL-17AA/AF inhibitor) and ZB022 (oral, brain-penetrant TYK2 inhibitor) are early-stage programs with best-in-class potential, expected to enter Phase 1 clinical trials in 2026.
• Obexelimab Phase 3 INDIGO trial (IgG4-RD) enrollment is complete with topline results expected around year-end 2025, potentially leading to a BLA submission in H1 2026.
• The MS market is projected to exceed $30 billion, with progressive forms representing over $12 billion, offering substantial commercial opportunity for orelabrutinib.

Negatives

• Orelabrutinib was placed on a partial clinical hold by the FDA for studies in RMS due to two cases of Drug-Induced Liver Injury (DILI) meeting Hys Law criteria, although Phase 3 progressive MS trials have been cleared with risk mitigation.
• The company has a limited operating history and anticipates incurring substantial and increasing losses for the foreseeable future.
• The company needs substantial additional financing to achieve its goals beyond the current cash runway.
• Uncertainty of clinical development, which is lengthy, expensive, and characterized by uncertain outcomes.
• The decision on advancing obexelimab for RMS will be made in early 2026, indicating potential discontinuation or redirection of that program.
• The $5 million deposit towards the InnoCare upfront payment has already reduced the cash balance as of September 30, 2025.

Risks

• Limited operating history and anticipation of substantial and increasing losses for the foreseeable future.
• Need for substantial additional financing to achieve goals.
• Uncertainty, length, and expense of clinical development, with risks of additional costs or delays in completing development and commercialization of product candidates.
• Delays or difficulties in patient enrollment and dosing in clinical trials.
• Impact of significant adverse events or undesirable side effects caused by product candidates, including hepatotoxicity events for orelabrutinib.
• Potential competition from large and specialty pharmaceutical and biotechnology companies with approved therapies.
• Ability to realize benefits of current or future collaborations or licensing arrangements and successfully consummate future partnerships.
• Ability to obtain regulatory approval for product candidates in the U.S. or other jurisdictions, and the risk of approval for a narrower indication.
• Dependence on senior management and other clinical and scientific personnel, and ability to retain/recruit them.
• Ability to grow and manage organizational expansion.
• Risks related to complex manufacturing of product candidates and potential difficulties with third-party manufacturers (e.g., WuXi Biologics in China).
• Ability to obtain and maintain sufficient intellectual property protection.
• Reliance on third parties to conduct preclinical studies and clinical trials.
• Compliance with obligations under licenses granted by others.
• Significant political, trade, and regulatory developments, including changes in U.S.-China relations.
• Risk that conditions to closing of the Private Placement are not satisfied.

Future Outlook

Zenas BioPharma anticipates several key milestones over the next two years, including reporting 12-week Phase 2 RMS data for obexelimab in early Q4 2025 and Phase 3 IgG4-RD topline data around year-end 2025. A Biologics License Application (BLA) submission for obexelimab in IgG4-RD is expected in the first half of 2026, with potential approval and launch in the first half of 2027. For orelabrutinib, a Phase 3 PPMS trial has initiated in Q3 2025, and a Phase 3 SPMS trial is expected to start in Q1 2026, with topline results targeted for 2030 for both. Early-stage candidates ZB021 and ZB022 are expected to have IND filings and Phase 1 initiations in 2026, with initial patient data in 2027. The company projects its cash, cash equivalents, and investments will fund operations into Q4 2026, extending into Q1 2027 with a potential $75 million milestone from Royalty Pharma.

Management Comments

• Lonnie Moulder (Founder and CEO of Zenas): "With global rights to orelabrutinib, we are advancing a potential blockbuster franchise for progressive MS. Orelabrutinib, with its best-in-class potential, is strongly positioned to address disease progression independent of relapse activity, the highest unmet medical need in MS, and to improve the lives of patients living with progressive MS. We are also excited to add two potentially best-in-class molecules, a novel, oral, IL-17AA/AF inhibitor and an oral, brain-penetrant, TYK2 inhibitor, to our pipeline. We plan to advance each of these programs to human clinical trials in 2026 and expect to have initial patient data from the oral IL-17AA/AF clinical program in 2027."
• Dr. Jasmine Cui (Co-Founder, Chairwoman and CEO of InnoCare Pharma): "We are delighted to partner with Zenas BioPharma. The partnership with Zenas BioPharma represents a significant milestone in our journey, and we will continue to enhance and advance our globalization efforts in the future. Orelabrutinib has a differentiated mechanism of action and strong clinical data underscoring its promising potential as a treatment for patients with progressive forms of MS."
• Lisa von Moltke (Head of Research and Development and Chief Medical Officer of Zenas): "BTK inhibition is a validated mechanism for the treatment of progressive forms of MS, and there is immense scientific interest in its potential to impact inflammation compartmentalized in the CNS and thereby potentially impact disability progression independent of relapse activity. We believe the differentiated, potentially best-in-class profile of orelabrutinib could make a meaningful difference for patients with PPMS and SPMS, which have few treatment options."

Industry Context

The license agreement positions Zenas BioPharma to capitalize on the growing market for autoimmune and neuroinflammatory diseases, particularly Multiple Sclerosis. The focus on CNS-penetrant BTK inhibitors like orelabrutinib aligns with a significant industry trend to address compartmentalized inflammation and neurodegeneration in progressive MS, an area with high unmet medical need and limited approved therapies. The acquisition of IL-17AA/AF and TYK2 inhibitors also reflects the industry's shift towards small molecules for targets validated by biologics in rheumatology and dermatology, as evidenced by recent acquisitions and partnerships in the space (e.g., Eli Lilly's acquisition of DICE Therapeutics). The company aims to build a multi-franchise, global, fully-integrated biopharmaceutical company, leveraging an experienced team and a disciplined product acquisition approach.

Comparison to Industry Standards

• Orelabrutinib's Phase 2 RRMS trial showed significant reductions in new GdE+ T1 lesions (e.g., 90.4% reduction at Week 12 for 80mg QD), which is comparable to or better than historical benchmarks for other BTK inhibitors like fenebrutinib (0.27 vs 0.03 at week 12) and tolebrutinib (1.03 vs 0.13 at week 12), and other therapies like frexalimab (1.40 vs 0.20 at week 12) and ofatumumab (1.3 vs 0.10 at week 12).
• Orelabrutinib is highlighted as having "best-in-class potential" due to its high selectivity, CNS penetration, and high potency, differentiating it from other BTK inhibitors like tolebrutinib and fenebrutinib.
• A peer BTKi (tolebrutinib) is under FDA review as the first therapy for non-relapsing/active SPMS, having significantly reduced disability progression in both SPMS and RRMS Phase 3 trials, validating BTK as a target for progressive MS.
• For PPMS, only one drug (Ocrevus) is approved, and for non-active SPMS, no drugs are approved, positioning orelabrutinib in a market with high unmet need and limited competition.
• The 60% placebo rate observed in the MITIGATE (Uplizna Phase 3) trial for IgG4-RD is cited as a derisking event for INDIGO assumptions, indicating that obexelimab's trial design is similar and potentially benefits from this benchmark.
• Obexelimab's Phase 2 IgG4-RD results (100% of patients met primary endpoint, 93% ongoing remission) are presented as robust, with 80% of prior rituximab patients achieving complete remission, suggesting strong efficacy compared to existing treatments.
• Anti-IL-17 biologics are noted as a "blockbuster drug class" with a $10 billion global market and 50% average annual growth, providing a strong market context for ZB021.

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline expansion, strengthened financial position, and progress towards commercialization. Dilution from new share issuance in private placement.
• Investors (new): Opportunity to invest in a company with an expanded pipeline and extended cash runway.
• InnoCare Pharma: Receives significant upfront and potential milestone payments, plus royalties, for licensing its assets. Becomes a significant shareholder in Zenas.
• Patients: Potential for new, transformative therapies for autoimmune diseases, especially progressive MS, IgG4-RD, and SLE.
• Employees: Potential for growth and stability within the company due to pipeline expansion and financing.

Next Steps

• Anticipated PIPE Closing on or about October 9, 2025.
• Zenas to file a registration statement for PIPE Shares within 15 days of PIPE Closing.
• Zenas to file a registration statement for InnoCare Shares by October 7, 2026.
• Expected reporting of 12-week primary endpoint results from Phase 2 MoonStone trial (obexelimab for RMS) early in Q4 2025.
• Expected reporting of topline results from Phase 3 INDIGO trial (obexelimab for IgG4-RD) around year-end 2025.
• Expected completion of enrollment in Phase 2 SunStone trial (obexelimab for SLE) around year-end 2025.
• Expected initiation of Phase 3 clinical trial for orelabrutinib in SPMS in Q1 2026.
• Expected reporting of 24-week data from Phase 2 MoonStone trial (obexelimab for RMS) in Q1 2026.
• Program decision for obexelimab in RMS anticipated in early 2026.
• Expected BLA submission for obexelimab in IgG4-RD in the first half of 2026 (if positive topline results).
• Expected IND filing and Phase 1 clinical development initiation for ZB021 and ZB022 in 2026.
• Expected reporting of topline results from Phase 2 SunStone trial (obexelimab for SLE) in mid-2026.
• Potential commercial launch of obexelimab in IgG4-RD in the U.S. and Europe in the first half of 2027 (if approved).
• Potential initiation of Phase 3 program for obexelimab in SLE in the first half of 2027 (based on SunStone outcome).
• Potential for initial patient data from ZB021 and ZB022 Phase 1 clinical programs in 2027.
• Goal to report topline results for orelabrutinib Phase 3 PPMS and SPMS studies in 2030.

Key Dates

Recommendation

The filing details a transformative license agreement that significantly expands the company's pipeline with three promising autoimmune product candidates, including a late-stage BTK inhibitor for progressive MS, a market with high unmet need and substantial commercial potential. The concurrent $120 million private placement financing strengthens the balance sheet and extends the cash runway, providing capital for advancing these programs. Despite a partial clinical hold for orelabrutinib in RMS, the FDA has cleared its Phase 3 progressive MS trials with risk mitigation, indicating a clear path forward for the most valuable indications. The progress of obexelimab in IgG4-RD and SLE also adds to the company's long-term value proposition. This strategic expansion and financial bolstering position Zenas BioPharma for significant future growth and potential market leadership in autoimmune diseases.

Keywords

Autoimmune diseases, Multiple Sclerosis (MS), BTK inhibitor, Orelabrutinib, Zenas BioPharma, InnoCare Pharma, Private Placement, Biopharmaceutical, Clinical trials, Drug development, Immunology, Inflammation, IgG4-RD, Systemic Lupus Erythematosus (SLE), Relapsing Multiple Sclerosis (RMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS), ZB021, IL-17AA/AF inhibitor, ZB022, TYK2 inhibitor, Obexelimab, SEC filing, Financing, Biotech